KR20110101743A - Compositions comprising hippophae rhamnoides l. leaves or extracts thereof for amelioration of body lipid - Google Patents
Compositions comprising hippophae rhamnoides l. leaves or extracts thereof for amelioration of body lipid Download PDFInfo
- Publication number
- KR20110101743A KR20110101743A KR1020100020969A KR20100020969A KR20110101743A KR 20110101743 A KR20110101743 A KR 20110101743A KR 1020100020969 A KR1020100020969 A KR 1020100020969A KR 20100020969 A KR20100020969 A KR 20100020969A KR 20110101743 A KR20110101743 A KR 20110101743A
- Authority
- KR
- South Korea
- Prior art keywords
- vitamin
- composition
- lipid
- vitamin tree
- fat
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 239000000284 extract Substances 0.000 title claims abstract description 26
- 150000002632 lipids Chemical class 0.000 title description 35
- 240000000950 Hippophae rhamnoides Species 0.000 title description 2
- 235000003145 Hippophae rhamnoides Nutrition 0.000 title description 2
- 239000011782 vitamin Substances 0.000 claims abstract description 95
- 229940088594 vitamin Drugs 0.000 claims abstract description 95
- 235000013343 vitamin Nutrition 0.000 claims abstract description 94
- 229930003231 vitamin Natural products 0.000 claims abstract description 94
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 91
- 239000000843 powder Substances 0.000 claims abstract description 77
- 208000008589 Obesity Diseases 0.000 claims abstract description 29
- 235000020824 obesity Nutrition 0.000 claims abstract description 29
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 26
- 230000037356 lipid metabolism Effects 0.000 claims abstract description 25
- 230000005856 abnormality Effects 0.000 claims abstract description 23
- 241001122767 Theaceae Species 0.000 claims description 35
- 235000013305 food Nutrition 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 54
- 210000004369 blood Anatomy 0.000 abstract description 23
- 239000008280 blood Substances 0.000 abstract description 23
- 235000012000 cholesterol Nutrition 0.000 abstract description 23
- 210000004185 liver Anatomy 0.000 abstract description 10
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 10
- 239000003925 fat Substances 0.000 description 55
- 230000000694 effects Effects 0.000 description 37
- -1 lipid peroxide Chemical class 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 18
- 210000002381 plasma Anatomy 0.000 description 17
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 210000001596 intra-abdominal fat Anatomy 0.000 description 15
- 238000010171 animal model Methods 0.000 description 13
- 235000009200 high fat diet Nutrition 0.000 description 13
- 201000001320 Atherosclerosis Diseases 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 235000018823 dietary intake Nutrition 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 9
- 108010082126 Alanine transaminase Proteins 0.000 description 9
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 9
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 210000005228 liver tissue Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 7
- 229920000084 Gum arabic Polymers 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 235000010489 acacia gum Nutrition 0.000 description 6
- 239000000205 acacia gum Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 206010019851 Hepatotoxicity Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 201000010063 epididymitis Diseases 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000007686 hepatotoxicity Effects 0.000 description 5
- 231100000304 hepatotoxicity Toxicity 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 238000010025 steaming Methods 0.000 description 5
- 244000215068 Acacia senegal Species 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000006371 metabolic abnormality Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000021910 Cerebral Arterial disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 244000165918 Eucalyptus papuana Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- XHTYQFMRBQUCPX-UHFFFAOYSA-N 1,1,3,3-tetramethoxypropane Chemical compound COC(OC)CC(OC)OC XHTYQFMRBQUCPX-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- XIDKOQJFNCSRAS-UHFFFAOYSA-N 2-propoxycarbonylbenzenecarboperoxoic acid Chemical compound CCCOC(=O)C1=CC=CC=C1C(=O)OO XIDKOQJFNCSRAS-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 206010003173 Arterial rupture Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 101100012567 Caenorhabditis elegans fat-1 gene Proteins 0.000 description 1
- 101100119770 Caenorhabditis elegans fat-5 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000292839 Ficus religiosa Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000985630 Lota lota Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 244000179886 Moringa oleifera Species 0.000 description 1
- 235000011347 Moringa oleifera Nutrition 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N Trimethylene glycol Natural products OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000020974 cholesterol intake Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229950010030 dl-alanine Drugs 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 235000021098 high calorie intake Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007603 infrared drying Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulphite Substances [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000021127 solid diet Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Abstract
본 발명은 비타민나무잎 분말 또는 이의 추출물을 포함하는 지질 대사 이상 개선 조성물에 관한 것으로, 본 발명의 조성물은 혈중 또는 간의 중성지방 또는 총 콜레스테롤을 감소시켜 개체 내 지질 대사 이상, 특히 고지혈증 또는 비만을 효과적으로 예방 또는 개선할 수 있다. The present invention relates to a composition for improving lipid metabolism abnormality comprising vitamin tree leaf powder or extract thereof, and the composition of the present invention reduces triglycerides or total cholesterol in blood or liver to effectively prevent lipid metabolism abnormalities, particularly hyperlipidemia or obesity in an individual. Can be prevented or improved.
Description
본 발명은 비타민나무잎 분말 또는 이의 추출물을 포함하는 고지혈증 또는 비만 등의 지질 대사 이상을 예방 또는 치료 혹은 개선용 조성물에 관한 것이다. 이러한 조성물은 고지혈증 또는 비만 등의 지질 대사 이상을 예방 또는 치료 혹은 개선을 위하여 의약품, 식품 또는 식품 소재로서 사용할 수 있다.
The present invention relates to a composition for preventing, treating or improving lipid metabolism abnormalities, such as hyperlipidemia or obesity, including vitamin tree leaf powder or extracts thereof. Such compositions can be used as pharmaceuticals, foods or food ingredients for the prevention, treatment or improvement of lipid metabolism abnormalities such as hyperlipidemia or obesity.
서구 식생활이 도입되면서 동물성 식품 및 가공식품 등을 통하여 열량의 섭취가 증가하고 있고, 성인병으로 비만, 당뇨병, 고혈압, 동맥경화 및 심혈관질환 등이 늘어나고 있다. 특히 동물성 지방의 과다한 섭취로 인한 혈액내의 고 콜레스테롤과 고 중성지방이 만성 성인병의 발병에 중요한 원인으로 여겨지고 있다.
With the introduction of Western diet, calorie intake is increasing through animal foods and processed foods, and obesity, diabetes, hypertension, arteriosclerosis, and cardiovascular diseases are increasing as adult diseases. In particular, high cholesterol and high triglycerides in the blood due to excessive intake of animal fats are considered to be an important cause of the development of chronic adult diseases.
혈중 콜레스테롤 농도는 콜레스테롤 섭취량에 따라 생합성이 조절되어 일정하게 유지되나 과량으로 섭취 시 여러 가지 대사성 질환을 유발한다. 고지방의 과도한 섭취는 가장 먼저 고지혈증으로 이어져 동맥경화를 유발하게 된다. 고지혈증(hyperlipedemia)은 혈액 중의 콜레스테롤, 중성지방(트리글리세라이드), 인지질 및 유리지방산 등의 농도가 비정상적으로 증가한 상태로서 가장 직접적으로 영향을 미치는 인자는 혈중 콜레스테롤과 저밀도지단백(LDL)-콜레스테롤을 들 수 있으며, 특히 고콜레스테롤혈증(hypercholesterolemia)은 죽상동맥경화증(atherosclerosis)을 유발하는 것으로 알려져 있다.
The blood cholesterol level is kept constant by adjusting biosynthesis according to cholesterol intake, but when ingested in excess, it causes various metabolic diseases. Excessive intake of high fat first leads to hyperlipidemia, leading to atherosclerosis. Hyperlipedemia is an abnormally elevated concentration of cholesterol, triglycerides, phospholipids, and free fatty acids in the blood. The most directly affecting factors are blood cholesterol and low density lipoprotein (LDL) -cholesterol. In particular, hypercholesterolemia is known to cause atherosclerosis.
죽상동맥경화증은 혈관벽을 따라 지질이 두껍게 쌓여 혈류를 감소시켜 허혈성 심장질환과 협심증, 심근경색의 원인이 되므로 임상적으로 중요한 문제가 되고 있다. 동맥경화란 동맥내벽에 지방질 및 섬유조직이 쌓여 혈관벽이 좁아지거나 막히게 되는 것으로, 고혈압, 고지혈증 및 흡연은 동맥경화 발생을 촉진시키는 3대 위험 요소이며, 이외에도 운동부족, 당뇨병, 비만증, 스트레스 등에 의해 발생률이 높아진다. 동맥경화가 가벼우면 활동에 지장은 없으나 동맥경화로 관상조직이 50 내지 70% 이상 좁아지거나 막히면 동맥경화성 심장병이 야기된다. 동맥경화증은 심한 경우 동맥의 파열이 일어나는 것으로 여러 순환계 질환, 즉 고혈압, 협심증, 뇌혈관질환(뇌일혈) 등의 주요 원인이 되고 있다.
Atherosclerosis is a clinically important issue because thick lipids build up along the blood vessel walls, reducing blood flow and causing ischemic heart disease, angina pectoris, and myocardial infarction. Arteriosclerosis is the narrowing or clogging of blood vessel walls due to the accumulation of fat and fibrous tissues in the arterial wall. Hypertension, hyperlipidemia, and smoking are the three major risk factors for promoting atherosclerosis. In addition, the incidence rate is caused by lack of exercise, diabetes, obesity, and stress. Is higher. If atherosclerosis is light, no activity is impeded, but atherosclerosis causes atherosclerotic heart disease if the coronary tissue is narrowed or blocked by 50 to 70% or more. Atherosclerosis is a severe artery rupture that is a major cause of various circulatory diseases, namely hypertension, angina, cerebrovascular disease (cerebral hemorrhage).
따라서 혈액내의 이들 지질 수준을 저하시키기 위한 치료 및 예방책의 일환으로 식생활에 대한 관심이 모아지고 있다. 식품에 대한 관심 역시 영양적인 측면이나 기호성을 고려한 1차적, 2차적 기능보다 질병의 치료 및 예방에 관계되는 3차적 기능에 더 관심이 많아지고 있다.
Therefore, attention has been drawn to diet as part of treatment and prevention measures to lower these lipid levels in the blood. The interest in food is also more concerned with the tertiary functions related to the treatment and prevention of diseases than the primary and secondary functions considering nutritional aspects or palatability.
한편, 비타민나무(Hippophae rhamnoides L.)는 보리수과에 속하는 과목으로서 100여종 이상의 성분을 포함하고 있으며, 특히 비타민 A, B, C, E, F, K 등의 유용한 성분을 많이 함유하고 있다. 겨울철 추위 및 여름철 고온에서도 잘 자라며, 척박한 지대에서도 잘 자라는 강한 적응성을 지녔다. 이미 비타민나무를 이용한 식품 등의 개발이 이루어지고 있는데, 예를 들면, 대한민국 특허공개 제2009-0127615호는 비타민나무의 열매를 분말차로 제조하는 방법에 대하여 개시하고 있고, 대한민국 특허공개 제2010-0006459호는 비타민나무의 맛과 향미, 영양분이 포함된 된장을 제조하는 방법에 대하여 개시하고 있다.
On the other hand, the vitamin tree ( Hippophae rhamnoides L.) is a subject belonging to the family Bodhi tree, which contains more than 100 kinds of components, especially vitamin A, B, C, E, F, K and many other useful components. It grows well in cold winters and in summers, and has a strong adaptability to grow well even in barren areas. Already, the development of foods using vitamin trees, etc. have been made, for example, Korean Patent Publication No. 2009-0127615 discloses a method for manufacturing the fruit of the vitamin tree as a powder tea, and Korean Patent Publication No. 2010-0006459 No. discloses a method of making miso containing the flavor, flavor and nutrients of vitamin trees.
최근 들어 이러한 비타민나무의 항산화 효과가 밝혀진 바 있으나, 혈중 콜레스테롤과 관련된 질환에 대한 효과에 대해서는 아직까지 밝혀진 바 없다.
Recently, the antioxidant effect of this vitamin tree has been revealed, but the effect on the blood cholesterol-related diseases have not been identified yet.
따라서 본 발명자들은 상기와 같은 관점에서 예의 연구를 거듭하여 동물실험을 통해 고지방식이로 유도한 지질 대사 이상에 대해 비타민나무가 체중 및 혈중 지질 성분 변화에 미치는 영향을 조사하고, 그의 혈중지질 개선 효능을 검증함으로써 본 발명에 이르게 되었다.
Therefore, the present inventors have conducted intensive research from the above point of view, and investigated the effect of the vitamin tree on the change in body weight and blood lipid components on lipid metabolism induced by high fat diet through animal experiments, and its blood lipid improving effect By verifying the present invention has been reached.
따라서 본 발명의 목적은 혈중지질개선 및 체지방감소 효과를 갖는 비타민나무의 새로운 용도를 제공하는 것이다.
Therefore, an object of the present invention is to provide a new use of the vitamin tree having a blood lipid improvement and body fat reduction effect.
본 발명은 비타민나무잎 분말 또는 이의 추출물을 포함하는 지질 대사 이상 개선 조성물을 제공한다.
The present invention provides a composition for improving lipid metabolism abnormality comprising vitamin tree leaf powder or extracts thereof.
본 발명의 비타민나무잎 분말은 비타민나무의 잎을 채취하여 세척한 후 이를 잘게 세절하거나 비타민나무의 잎을 채취하여 세척한 후 이를 덖음하고 잘게 세절한 것을 말한다. 상기 세절은 믹서기 또는 분쇄기 등의 통상의 세절기를 이용하여 잘게 절단한 것으로 세절된 비타민나무잎 분말의 입도 크기는 하기에서 상술하는 적용 형태에 따라 상이할 수 있으나, 입도 크기가 40∼60 메쉬(mesh)인 분말이 개체에 투여되거나 개체가 섭취하기에 용이하므로 상기 범위의 입도 크기를 가지는 것이 바람직하다.
Vitamin tree leaf powder of the present invention refers to the finely chopped and finely chopped leaves after harvesting and washing the leaves of the vitamin tree or chopped and finely chopped after the leaves of the vitamin tree. The fine cutting is finely cut using a conventional cutting machine such as a mixer or a pulverizer, the particle size of the sliced vitamin tree leaf powder may be different depending on the application form described in detail below, the particle size is 40 to 60 mesh ( It is preferable to have a particle size in the above range because the powder, which is a mesh), is easily administered to the subject or consumed by the subject.
본 발명에서 상기 덖음은 물을 가하지 않고 타지 않을 정도로 가열기에서 볶아 익힌 것을 말한다. 덖음을 위한 가열 온도는 40 내지 400℃, 바람직하게는 50 내지 360℃, 보다 바람직하게는 60 내지 350℃이며, 덖음의 회수는 1회 이상, 바람직하게는 2회 이상, 보다 바람직하게는 3회 이상, 보다 더 바람직하게는 3 내지 5회, 가장 바람직하게는 4회이다. 또한, 덖음 시간은 1 내지 15분, 바람직하게는 2분 내지 12분, 보다 바람직하게는 3분 내지 10분이다. 상기 덖음은 덖음의 회수에 따라 각기 가열 온도 및 시간을 상이하게 하여 이루어질 수 있으며, 이들 덖음 회수, 가열 온도 및 시간은 비타민나무잎의 채취 시기, 크기 및 잎의 강도 등에 따라 달리 선택하여 실시될 것이다. 하나의 구체적 실시에서, 상기 덖음은 350℃에서 3분간 살청하여 꺼낸 다음 5분간 비비고, 200℃에서 5분간 덖고 꺼내어 비빈 후 150℃에서 덖고 비빈 다음 100℃ 이하에서 10분간 덖음으로써 실시할 수 있다.
In the present invention, the steaming refers to cooked and roasted in a heater so that it does not burn without adding water. The heating temperature for steaming is 40-400 degreeC, Preferably it is 50-360 degreeC, More preferably, it is 60-350 degreeC, The collection | recovery of steaming is 1 or more times, Preferably it is 2 or more times, More preferably, 3 times More preferably, it is 3 to 5 times, most preferably 4 times. In addition, the extraction time is 1 to 15 minutes, preferably 2 minutes to 12 minutes, and more preferably 3 minutes to 10 minutes. The noise may be made by different heating temperature and time depending on the number of times of recovery, and the number of times of recovery, heating temperature and time will be carried out by selecting differently depending on the harvest time, size and strength of the leaves of the vitamin tree. . In one specific implementation, the steaming can be carried out by agitation at 350 ° C. for 3 minutes and then rubbing for 5 minutes, steaming at 200 ° C. for 5 minutes, taking out and emptying at 150 ° C., and then boiling at 150 ° C. for 10 minutes at 100 ° C. or less.
본 발명의 비타민나무잎 분말의 추출물은 상기의 비타민나무잎 분말을 통상의 방법에 의하여 추출하거나 이로부터 분리된 지질 대사 이상 개선의 효과를 가지는 물질을 말한다. 또한, 상기 추출물은 통상의 방법에 의하여 비타민나무잎 분말로부터 추출한 추출액뿐만 아니라 이의 건조 분말 또는 이를 이용하여 제형화된 모든 형태를 말한다.
Extract of the vitamin tree leaf powder of the present invention refers to a substance having the effect of improving the lipid metabolism abnormality extracted or separated from the vitamin tree leaf powder of the conventional method. In addition, the extract refers to not only the extract extracted from the vitamin tree leaf powder by a conventional method, but also its dry powder or any form formulated using the same.
본 발명에서 비타민나무잎 분말의 추출물은 물 (예, 정제수, 증류수, 수돗물 등) 또는 유기 용매를 사용하여 추출할 수 있는데, 추출한 액은 액체 형태로 사용하거나 또는 농축 및/또는 건조하여 사용할 수 있다. 상기 유기용매는 메탄올, 에탄올, 이소프로판올, 부탄올, 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N, N-디메틸포름아미드(DMF), 디메틸설폭사이드(DMSO), 1,3-부틸렌글리콜, 프로필렌글리콜 또는 이들의 혼합용매이며, 추출물의 유효 성분이 파괴되지 않거나 최소화된 조건에서 실온 또는 가온하여 추출할 수 있다. 추출하는 유기용매에 따라 추출물의 유효성분의 추출정도와 손실정도가 차이가 날 수 있으므로, 알맞은 유기용매를 선택하여 사용하도록 한다. 추출 방법은 특별히 제한되지 않고, 예를 들어 냉침 추출, 초음파 추출, 환류 냉각 추출 등이 있다.In the present invention, the extract of the vitamin tree leaf powder may be extracted using water (eg, purified water, distilled water, tap water, etc.) or an organic solvent, and the extracted liquid may be used in liquid form, or concentrated and / or dried. . The organic solvent is methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N- dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1 , 3-butylene glycol, propylene glycol, or a mixed solvent thereof, and can be extracted at room temperature or warmed under conditions in which the active ingredient of the extract is not destroyed or minimized. Depending on the organic solvent to be extracted, the degree of extraction and loss of the active ingredient of the extract may vary, so select an appropriate organic solvent. The extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like.
여과는 추출액으로부터 부유하는 고체 입자를 제거하는 과정으로, 면, 나일론 등을 이용하여 입자를 걸러 내거나 한외여과, 냉동여과법, 원심분리법 등을 사용할 수 있으나, 이에 제한되지 않는다. 또한, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 크로마토그래피)에 의한 분리 과정을 추가로 포함할 수 있다.Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, ultrafiltration, cryofiltration, centrifugal separation, etc., but is not limited thereto. It may also further comprise a separation process by various chromatography (chromatography according to size, charge, hydrophobicity or affinity).
여액을 건조하는 단계는 동결건조, 진공건조, 열풍건조, 분무건조, 감압건조, 포말건조, 고주파건조, 적외선건조 등을 포함하나 이에 제한되지 않는다. 경우에 따라, 최종 건조된 추출물을 분쇄하는 공정을 추가할 수 있다.
Drying the filtrate includes, but is not limited to, lyophilization, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, infrared drying, and the like. If desired, a process of grinding the final dried extract may be added.
본 발명에 있어서, "지질 대사 이상"은 생체의 지질 성분의 밸런스에 이상이 인정되는 상태를 말해, 예를 들면 고지혈증, 또는 간장에 있어서의 콜레스테롤이나 중성 지방의 축적 등을 들 수 있다. 고지혈증은, 예를 들면 혈중의 총콜레스테롤, LDL(저비중 리포 단백)콜레스테롤, 중성 지방(TG) 등이 높은 수치를 나타내는 상태, 또는 혈중 HDL(고비중 리포 단백) 콜레스테롤이 낮은 수치를 나타내는 상태 등이 포함된다. 지질 대사 이상은, 상기 생체의 지질 밸런스에 이상이 인정되는 상태이면, 그 원인은 제한되지 않고, 예를 들면 고지방식에 의해 야기되는 경우, 혹은 통상의 식생활에 있어 연령이나 운동부족 등에 의해 야기 되는 경우를 포함한다. 상기 고지혈증은, 동맥경화증의 진전에 중대한 영향을 미칠 수 있다. 동맥경화증은 동맥벽 내강이 협착이나 폐색을 가져오고, 혈류 저하를 수반하고, 예를 들면 일과성 뇌허혈발작, 뇌경색, 심근경색, 협심증 등을 포함한 각종 병의 용태를 일으키는 원인이 될 수 있다. 또한, 지질 대사 이상은 비만과의 관련을 들 수 있다. 비만은 신체에 지방이 과잉 축적된 상태를 말하며, 이에는 내장 지방 축적형 비만이 포함된다.
In the present invention, "lipid metabolism abnormality" refers to a state in which abnormality is recognized in the balance of lipid components of a living body, and examples thereof include hyperlipidemia or accumulation of cholesterol and triglycerides in the liver. Hyperlipidemia is, for example, a condition showing high levels of total cholesterol, LDL (low specific lipoprotein) cholesterol, triglyceride (TG), or the like, or low levels of HDL (high specific lipoprotein) cholesterol in the blood. This includes. The lipid metabolism abnormality is a condition in which the abnormality is recognized in the lipid balance of the living body, and the cause thereof is not limited. For example, the lipid metabolism abnormality may be caused by age or lack of exercise in the diet. Includes cases. The hyperlipidemia can have a significant effect on the development of atherosclerosis. Atherosclerosis causes arterial wall lumen stenosis and obstruction, accompanied by a decrease in blood flow, and can cause various conditions including, for example, transient cerebral ischemic attack, cerebral infarction, myocardial infarction, angina pectoris and the like. In addition, lipid metabolic abnormalities may be related to obesity. Obesity refers to a condition in which the body has an excessive amount of fat, which includes visceral fat accumulation type obesity.
또한, 상기 고지혈증 또는 비만 (특히 내장 지방 축적형 비만)은, 각각 단독으로도 상기한 각종 병의 용태를 일으킬 수 있지만, 이러한 병이 중복되는 병의 용태, 예를 들면 대사증후군에 있어서는, 동맥 경화를 촉진하고, 더 나아가 치명적인 심근경색이나 뇌경색 등을 일으키기 쉽다. 본 발명에 사용되는 비타민나무잎 분말 또는 이의 추출물을 함유하는 조성물은, 상기 고지혈증 또는 비만을 억제할 수 있으므로 대사증후군도 억제할 수 있다.
In addition, the hyperlipidemia or obesity (especially visceral fat accumulation type obesity) can cause the above-mentioned conditions of the various diseases alone, but in the condition of the overlapping of these diseases, for example, metabolic syndrome, atherosclerosis It is also easy to cause fatal myocardial infarction or cerebral infarction. The composition containing the vitamin leaf powder or an extract thereof used in the present invention can suppress the hyperlipidemia or obesity, and therefore can also suppress metabolic syndrome.
본 발명의 조성물은, 지질 대사 이상, 예를 들면 고지방식이나 연령 또는 운동 부족 등에 의해 야기되는 혈중이나 간의 중성지방 또는 총 콜레스테롤 또는 내장지방의 상승을 개선할 수 있다.
The composition of the present invention can improve the elevation of triglycerides or total cholesterol or visceral fat in the blood or liver caused by abnormal lipid metabolism, for example, high fat diet, age or lack of exercise.
본 발명의 조성물은, 지질 대사 이상을 개선할 수 있는 것으로부터 고지혈증을 예방 또는 치료, 혹은 개선할 수 있다. 더욱이 상기 고지혈증의 예방 또는 치료, 혹은 개선은 고지혈증에 기인하는 심장이나 뇌에 있어서의 동맥 경화, 예를 들면 뇌경색과 같은 뇌동맥 질환이나 협심증, 심근 경색 등의 관동맥 질환 등을 방지할 수 있다.
The composition of the present invention can prevent or treat or improve hyperlipidemia since it can improve lipid metabolism abnormality. Furthermore, the prevention, treatment, or improvement of the hyperlipidemia can prevent atherosclerosis in the heart or brain caused by hyperlipidemia, for example, cerebral artery disease such as cerebral infarction, coronary artery disease such as angina pectoris, myocardial infarction, and the like.
또한, 본 발명의 조성물은, 비만, 특히 내장 지방이 축적되는 내장 지방 축적형 비만을 예방 또는 개선할 수 있다. 내장 지방 축적형 비만은 당뇨병이나 고혈압 등의 생활 습관병의 발단이 되므로, 내장 지방 축적형 비만의 예방 또는 개선은 생활 습관병의 예방 또는 치료, 혹은 개선으로 연결될 수 있다. 특히, 본 발명의 조성물은, 대변을 통한 지방의 배출량을 증가시키므로 음식의 장내 통과시간이 단축된다. 이러한 단축은 장내에서의 지질의 흡수를 억제하게 되어 비만의 예방에 도움이 된다.
In addition, the composition of the present invention can prevent or improve obesity, particularly visceral fat accumulation type obesity in which visceral fat accumulates. Visceral fat accumulation type obesity is the beginning of lifestyle diseases such as diabetes or high blood pressure, prevention or improvement of visceral fat accumulation type obesity can lead to prevention or treatment or improvement of lifestyle diseases. In particular, the composition of the present invention increases the amount of fat discharged through the feces, thereby reducing the intestinal transit time of food. This shortening helps to inhibit the absorption of lipids in the intestine, which helps prevent obesity.
본 발명에서 사용된 용어, "예방"이란 조성물의 투여로 지질 대사 이상, 예를 들어 고지혈증 및 비만의 발병을 억제 또는 지연시키는 모든 행위를 의미하며, "치료"란 조성물의 투여로 지질 대사 이상, 예를 들어 고지혈증 및 비만으로 인한 혈중 또는 간의 중성지방 또는 총 콜레스테롤을 정상 상태로 회복하는 모든 행위를 의미한다. 또한, 본 발명에서 사용된 용어, "개선"이란 조성물의 투여로 지질 대사 이상, 예를 들어 고지혈증 및 비만으로 인한 혈중 또는 간의 중성지방 또는 총 콜레스테롤의 감소시키는 모든 행위를 의미한다. 상기에서, "투여"는 개체의 경구 또는 비경구를 통한 개체 내 흡수 또는 섭취를 말한다. 또한, 상기“개체”는 지질 대사 이상의 직, 간접적 원인에 의해 유발된 질환, 예를 들어 고지혈증 또는 비만을 가지고 있으며, 본 발명의 상기 조성물을 투여하여 증상이 호전될 수 있는 질환을 가진 인간을 포함한 원숭이, 소, 말, 돼지, 양, 개, 고양이, 래트, 마우스, 침팬지 등의 포유동물을 의미한다.
As used herein, the term "prevention" means any action that inhibits or delays the development of lipid metabolism abnormalities, such as hyperlipidemia and obesity, by administration of the composition, and "treatment" means lipid metabolism abnormalities by administration of the composition, For example, it refers to any act of restoring triglycerides or total cholesterol in the blood or liver due to hyperlipidemia and obesity. In addition, as used herein, the term "improvement" refers to any action that reduces administration of triglycerides or total cholesterol in the blood or liver due to lipid metabolic abnormalities, such as hyperlipidemia and obesity, by administration of the composition. In the above, “administration” refers to absorption or ingestion of an individual through oral or parenteral administration of the individual. In addition, the "individual" is a disease caused by a direct or indirect cause of abnormal lipid metabolism, such as hyperlipidemia or obesity, including a human with a disease that can improve symptoms by administering the composition of the present invention Mammals such as monkeys, cows, horses, pigs, sheep, dogs, cats, rats, mice, and chimpanzees.
본 발명의 조성물을 투여함으로써, 몸무게를 감량할 수 있고 혈중, 간조직, 심장조직 내 등의 콜레스테롤 및 중성지질 등의 함량을 감소시켜 지질 대사 이상을 예방, 치료 또는 개선할 수 있다. 하나의 구체적 실시에서, 고지방(열량의 37%를 지방으로 대체)을 급여한 마우스에게 비타민나무잎 분말 또는 차분말을 식이에 수준별(1%와 5%)로 첨가하여 6주간 급여한 결과 체중은 비타민나무잎 분말 또는 차분말 급여시 고지방대조군에 비하여 감소하였으며, 체중단위당 부고환 무게는 비타민나무잎 차분말 급여시 고지방대조군에 비하여 22 내지 30%의 유의적인 감소를 보였으며, 장간막무게 역시 감소경향을 보임으로써 총 내장지방 무게량이 유의적으로 감소되었다. 그러나 비타민나무잎 분말 또는 차분말은 식이섭취량에는 영향을 미치지 않았다. 비타민나무잎 분말 또는 차분말 급여시 고지방대조군에 비하여 혈장의 중성지질, 총 콜레스테롤 및 간조직 중의 콜레스테롤 함량을 유의적으로 낮추었으며, 간조직 중의 중성지질 함량은 5% 급여군에서만 유의적인 감소를 보였다. 반면, 변으로 지질 배설은 비타민나무잎 분말 또는 차분말 급여시 고지방대조군에 비하여 유의적으로 증가하였다. 간독성 지표 효소인 혈중 GPT 활성은 비타민나무잎 분말 또는 차분말 급여시 유의적으로 개선되었으며, 혈중 GOT 활성은 비타민나무잎 분말 급여시 유의적으로 개선되었다. 그리고 적혈구의 지질과산화물 함량 역시 유의적으로 낮았다. 이와 같이 비타민나무잎 분말 또는 차분말은 고지방식이로 인한 체내 내장지방 축적을 억제할 뿐만 아니라 지질개선에 효과적이다.
By administering the composition of the present invention, it is possible to lose weight and to reduce the content of cholesterol, triglycerides and the like in the blood, liver tissue, heart tissue and the like to prevent, treat or improve abnormal lipid metabolism. In one specific example, mice fed high fats (37% of their calories replaced with fat) were fed with vitamin tree leaf powder or tea powder at different levels (1% and 5%) in their diet for six weeks. Vitamin tree leaf powder or tea powder supplementation decreased compared to the high fat control group, and epididymal weight per unit of weight decreased significantly by 22 to 30% compared to the high fat control group, and mesenteric weight was also decreased. As shown, total visceral fat weight was significantly reduced. However, vitamin tree leaf powder or tea powder did not affect dietary intake. When fed the vitamin leaf powder or tea powder, the triglyceride, total cholesterol and cholesterol content in the liver were significantly lowered compared to the high fat control group, and the triglyceride content in the liver was significantly decreased only in the 5% feed group. . On the other hand, stool lipid excretion was significantly increased compared to the high fat control group when supplemented with vitamin leaf powder or tea powder. Serum GPT activity, which is a marker of hepatotoxicity, was significantly improved when vitamin leaf powder or tea powder was fed, and blood GOT activity was significantly improved when vitamin leaf powder was fed. The lipid peroxide content of erythrocytes was also significantly lower. As such, vitamin tree leaf powder or tea powder is effective in improving lipids as well as inhibiting accumulation of visceral fat due to high fat diet.
본 발명의 조성물은 비타민나무잎 분말 또는 이의 추출물을 배합하는 것에 의해 제조되어 의약품, 식품 또는 식품 소재로서 이용할 수 있다. 의약품으로서 이용하는 경우에는, 해당 비타민나무잎 분말 또는 이의 추출물과 약제학적으로 허용가능한 제재용 첨가물을 포함한 약제학적 조성물의 형태로 투여하는 것이 바람직하다. 약제학적 조성물은, 예를 들어, 캅셀제, 정제(당의정 또는 장용정 등의 코팅정 또는 다층정을 포함한다), 가루약 혹은 과립제 등의 경구 고형 제재의 형태를 취하고 있어도 좋고, 경구 액체 제재의 형태를 취하고 있어도 좋고, 주사제나 점적제, 좌제 등의 비경구 제재의 형태를 취하고 있어도 좋다.
The composition of the present invention can be prepared by blending vitamin tree leaf powder or extracts thereof, and can be used as medicines, foods or food materials. When used as a medicine, it is preferable to administer in the form of a pharmaceutical composition containing the vitamin leaf powder or extract thereof and a pharmaceutically acceptable additive for preparation. The pharmaceutical composition may take the form of oral solid preparations, such as capsules, tablets (including coated tablets such as dragees or enteric tablets or multilayer tablets), powdered medicines or granules, and take the form of oral liquid preparations. It may be present and may be in the form of parenteral preparations such as injections, drops, and suppositories.
캅셀제, 정제, 가루약 혹은 과립제 등의 고형 제재에 통상 사용되고 있는 제재용 첨가물로서는, 예를 들어, 부형제(예: 유당, 백당, 포도당, 전분, 결정 셀룰로오스 등), 결합제 [예: 전분호액, 히드록시 프로필 셀룰로오스액, 카르멜로스액(carmellose), 아라비아 고무액, 젤라틴액, 알긴산나트륨액 등], 붕괴제(예: 전분, 카르멜로스나트륨, 탄산칼슘 등), 활택제(예: 스테아린산 마그네슘, 탈크, 스테아린산, 스테아린산 칼슘 등), 계면활성제(예: 폴리소르베이트80, 폴리옥시 에틸렌 경화 피마자유 등), 증점제(예: 히드록시 에틸 셀룰로오스, 히드록시 프로필 셀룰로오스, 폴리비닐 알코올, 폴리에틸렌글리콜 등) 등을 들 수 있지만, 이들로 한정되지 않는다. 정제 또는 과립제는, 코팅제 [예: 젤라틴, 백당, 아라비아고무, 카나우바왁스(carnauba wax), 초산프탈산셀룰로오스, 메타크릴산 공중합체, 히드록시 프로필셀룰로오스프탈레이트, 카복시메틸에틸셀룰로오스, 히드록시 프로필 메틸 셀룰로오스 등] 등으로 제피를 해도 좋다. 캅셀제는, 하드 캅셀 외, 마이크로 캅셀 또는 소프트 캅셀 등도 좋다. 고형 제재는, 공지의 방법에 의해 제조할 수가 있다.
Examples of additives commonly used in solid preparations such as capsules, tablets, powdered medicines or granules include, for example, excipients (e.g. lactose, white sugar, glucose, starch, crystalline cellulose, etc.), binders [e.g. starch solution, hydroxy). Propyl cellulose solution, carmellose, gum arabic, gelatin, sodium alginate], disintegrants (e.g. starch, sodium carmellose, calcium carbonate, etc.), glidants (e.g. magnesium stearate, talc, Stearic acid, calcium stearate, etc.), surfactants (e.g.
액체 제재에는, 예를 들어, 당류[예: 자당, 솔비톨, 과당 등], 글리콜 류(예: 폴리에틸렌글리콜, 프로필렌글리콜 등), 분산 또는 증점제(예: 젤라틴, 아라비아고무, 히드록시 에틸 셀룰로오스, 히드록시 프로필 셀룰로오스, 폴리비닐 알코올, 폴리에틸렌글리콜 등), 유화제(예: 글리세린 지방산 에스테르, 자당 지방산 에스테르 등), 용해 보조제(예: 아라비아고무, 폴리소르베이트 80 등), pH조정제(예: 시트르산, 시트르산삼나트륨 등), 방부제(예: 파라옥시 안식향산에스테르류 등) 등을 배합해도 좋다.
Liquid preparations include, for example, sugars (e.g. sucrose, sorbitol, fructose, etc.), glycols (e.g. polyethylene glycol, propylene glycol, etc.), dispersing or thickening agents (e.g. gelatin, gum arabic, hydroxy ethyl cellulose, hydride). Oxypropyl cellulose, polyvinyl alcohol, polyethylene glycol, etc.), emulsifiers (e.g. glycerin fatty acid esters, sucrose fatty acid esters, etc.), dissolution aids (e.g. gum arabic,
비경구 투여에 적절한 제재 중 주사제나 링겔제 등의 혈관 내 투여용 제재는, 바람직하게는 체액 등과 장의 수성 매체를 이용하여 조제할 수 있다. 예를 들면, 주사제는, 주사용 증류수, 소금 용액, 포도당 용액 또는 소금 용액과 포도당 용액의 혼합물로부터 선택되는 수성 매체를 이용하여 일반적인 방법에 따라 적당한 조제와 함께 용액, 현탁액 또는 분산액으로 조제할 수 있다. 장내 투여를 위한 좌제는, 예를 들면 카카오 지방, 수소화 지방 또는 수소첨가 카르복시산 등의 담체를 이용하여 조제할 수 있다.
Among the preparations suitable for parenteral administration, preparations for intravascular administration such as injections or ring gels can be preferably prepared using body fluids or intestinal aqueous media. For example, injectables can be formulated in solution, suspension or dispersion with suitable preparations in accordance with conventional methods using aqueous media selected from distilled water, salt solutions, glucose solutions or mixtures of salt and glucose solutions for injection. . Suppositories for enteral administration can be prepared, for example, using a carrier such as cacao fat, hydrogenated fat or hydrogenated carboxylic acid.
또한, 식품에 비타민나무잎 분말 또는 이의 추출물을 사용할 수 있다. 상기 식품은 비타민나무잎 분말 또는 이의 추출물을 그대로 이용해도 좋지만, 일반적으로는, 해당 비타민나무잎 분말 또는 이의 추출물과 식품위생상 허용되는 첨가물, 혹은 통상의 식품 원료를 포함한 형태로 하는 것이 바람직하다. 식품 소재는, 비타민나무잎 분말 또는 이의 추출물을 그대로 사용하는 형태여도 되고, 혹은 식품위생상 허용되는 첨가제를 포함한 형태여도 좋다.
In addition, vitamin tree leaf powder or extracts thereof may be used in the food. Although the said foodstuff may use vitamin tree leaf powder or its extract as it is, generally, it is preferable to set it as the form containing the said vitamin tree leaf powder or its extract, food hygiene acceptable additives, or a normal food raw material. The food material may be in the form of using vitamin tree leaf powder or its extract as it is, or may be in the form of an additive which is acceptable for food hygiene.
해당 식품이나 식품 소재는, 식품위생상 허용되는 첨가제와 함께, 예를 들면, 캅셀제, 정제(당의정 등의 코팅정 또는 다층정, 혹은 구강 붕괴제 등을 포함한다), 가루약 혹은 과립제 등의 고형 조성물의 형태를 취하고 있어도 좋고, 액체 조성물의 형태를 취하고 있어도 좋다. 해당 첨가제로서는, 예를 들면 부형제 (예: 유당, 덱스트린, 옥수수 전분, 결정 셀룰로오스 등), 활택제 (예: 스테아린산마그네슘, 자당 지방산 에스테르, 글리세린 지방산 에스테르 등), 붕괴제(예: 카르복시 메틸 셀룰로오스 칼슘, 무수인산수소칼슘, 탄산칼슘 등), 결합제(예: 전분호액, 히드록시 프로필 셀룰로오스액, 아라비아 고무액 등), 용해 보조제(예: 아라비아고무, 폴리소르베이트 80 등), 감미료[예: 설탕, 과당, 포도당액당, 벌꿀, 아스파르탐(aspartame)등], 착색료 (예: β-카로틴, 식용 타르 색소, 리보플라빈 등), 보존료(예: 소르빈산, 파라옥시 안식향산메틸, 아황산 나트륨 등), 증점제(예: 알긴산나트륨, 카르복시메틸 셀룰로오스 나트륨, 폴리 아크릴산 나트륨 등), 산화 방지제(예: 디부틸 히드록시 톨루엔, 부틸히드록시아니솔, 아스코르브산, 토코페롤 등), 향료(예: 박하, 딸기 향료 등), 산미료(예: 시트르산, 유당, DL－사과산 등), 조미료(예: DL－알라닌, 5＇－이노신산나트륨, L－글루타민산 나트륨 등), 유화제(예: 글리세린 지방산 에스테르, 자당 지방산 에스테르 등), pH조정제(예: 시트르산, 시트르산삼나트륨 등), 비타민류, 미네랄류, 아미노산류, 색소 등을 들 수 있다. 고형 조성물은, 일반적인 방법에 따라 제조할 수가 있다. 또한, 액체 조성물은, 상기 경구투여에 적절한 액체 제재와 같게 해 제조할 수가 있다.
The food and the food material together with additives acceptable in food hygiene include, for example, solid compositions such as capsules, tablets (including coated tablets such as dragees or multilayer tablets, oral disintegrating agents), powdered medicines and granules. It may take the form of and may take the form of a liquid composition. Examples of such additives include excipients (e.g. lactose, dextrin, corn starch, crystalline cellulose, etc.), glidants (e.g. magnesium stearate, sucrose fatty acid esters, glycerin fatty acid esters, etc.), disintegrants (e.g. carboxymethyl cellulose calcium). , Anhydrous calcium hydrogen phosphate, calcium carbonate, etc.), binders (e.g. starch solution, hydroxypropyl cellulose solution, gum arabic solution, etc.), dissolution aids (e.g. gum arabic,
또, 비타민나무잎 분말 또는 이의 추출물 혹은 이를 포함한 고형 조성물 및 액체 조성물을 음식에 배합하는 것에 의해 본 발명과 관련되는 식품을 제조할 수 있다. 그러한 식품으로서는, 예를 들면, 과자류[예: 껌, 캔디, 카라멜, 초콜릿, 쿠키, 스넥 과자, 젤리, 구미(과즙 등을 젤라틴으로 굳힌 과자의 일종), 정과 등], 면류(예: 국수, 우동, 라면 등), 유제품(예: 밀크, 아이스크림, 요구르트 등), 조미료(예: 된장, 간장 등), 스프류, 음료(예: 주스, 커피, 홍차, 차, 탄산음료, 스포츠 음료 등)를 비롯한 일반 식품이나 영양 보조 식품(예: 영양 드링크 등) 등을 들 수 있다. 덧붙여 식품에는, 식품 소재를 포함한 식품도 포함된다.
Moreover, the foodstuff concerning this invention can be manufactured by mix | blending a vitamin tree leaf powder or its extract, or a solid composition and liquid composition containing the same with food. Such foods include, for example, sweets (e.g. chewing gum, candy, caramel, chocolate, cookies, snack sweets, jelly, gummi (a kind of condensed cake with gelatin), sweets, etc.), noodles (e.g. noodles, Udon, ramen, etc.), dairy products (e.g. milk, ice cream, yogurt, etc.), seasonings (e.g. miso, soy sauce, etc.), soups, drinks (e.g. juice, coffee, tea, tea, soda, sports drinks, etc.) General foods and nutritional supplements (such as nutritional drinks). In addition, food includes food material.
상기 비타민나무잎 분말 또는 이의 추출물을 배합한 식품을 섭취하는 것으로, 예를 들면 혈중이나 간장 내의 콜레스테롤 및 중성 지방을 저하시키는 등, 지질 대사 이상을 개선해 고지혈증, 비만을 개선할 수 있다.
By ingesting the food containing the vitamin tree leaf powder or extracts thereof, for example, it is possible to improve hyperlipidemia and obesity by improving lipid metabolism abnormalities such as lowering cholesterol and triglycerides in blood or liver.
본 발명의 조성물에서의 비타민나무잎 분말 또는 이의 추출물의 배합량은 조성물 전체에 대해서 통상 약 0.01~80 질량% 배합하는 것이 바람직하다.
It is preferable to mix | blend the compounding quantity of the vitamin tree leaf powder or its extract in the composition of this invention normally about 0.01-80 mass% with respect to the whole composition.
본 발명의 조성물을 식품 또는 식품 소재로서 이용하는 경우, 지질 대사 이상 개선 효과, 혹은 고지혈증 또는 비만에 대해서 뛰어난 효과를 가진 비타민나무잎 분말 또는 이의 추출물을 함유하므로, 지질 대사 이상 개선 효과, 혹은 고지혈증 또는 비만 개선을 위해서 이용된다는 취지의 표시를 식품 또는 식품 소재의 포장 등에 붙이는 것이 바람직하다.
When the composition of the present invention is used as a food or a food material, it contains a vitamin tree leaf powder or an extract thereof having an effect of improving lipid metabolism abnormality or an excellent effect on hyperlipidemia or obesity, and thus, an effect of improving lipid metabolism abnormality, or hyperlipidemia or obesity. It is preferable to attach a mark indicating that it is to be used for improvement to package food or food materials.
또한, 본 발명의 조성물은, 지질 대사 이상 개선 효과, 혹은 고지혈증 또는 비만 개선을 위해서 이용되는 보건 기능 식품, 바람직하게는 특정 보건용 식품이 될 수 있다.
In addition, the composition of the present invention can be a health functional food, preferably a specific health food used for improving lipid metabolism abnormality or improving hyperlipidemia or obesity.
본 발명의 조성물은, 지질 대사 이상 개선 효과, 혹은 고지혈증 또는 비만의 예방 또는 치료에 사용할 수 있어 본 발명의 의약품, 식품 또는 식품소재는 지질 대사 이상 개선 효과, 혹은 고지혈증 또는 비만의 억제, 개선 등에 사용할 수 있다. 게다가 본 발명의 조성물은, 지질 대사이상, 혹은 고지혈증 또는 비만에 부수하는 각종 질환, 예를 들면, 고혈압증 또는 동맥경화증(예를 들면, 뇌경색과 같은 뇌동맥 질환, 협심증, 심근경색 등의 관동맥 질환) 등의 예방 및 치료, 혹은 이러한 각종 질환의 발증을 억제해 이러한 각종 질환의 병의 용태 개선 등에 사용할 수 있다.
The composition of the present invention can be used to improve lipid metabolism abnormality, or to prevent or treat hyperlipidemia or obesity, and the medicine, food or food material of the present invention can be used to improve lipid metabolism abnormality or to suppress or improve hyperlipidemia or obesity. Can be. In addition, the composition of the present invention, lipid metabolism abnormalities, hyperlipidemia or various diseases accompanying obesity, for example, hypertension or atherosclerosis (for example, cerebral artery diseases such as cerebral infarction, angina pectoris, myocardial infarction, etc.) It can be used for the prevention and treatment of the disease, or to suppress the onset of these various diseases and to improve the condition of the diseases of these various diseases.
본 발명의 비타민나무잎 분말 또는 이의 추출물은 개체의 몸무게를 감량할 수 있고 혈중, 간조직 및 심장조직 내 등의 콜레스테롤 및 중성지질 등의 함량을 감소시켜 개체 내 지질 대사 이상, 예를 들면 고지혈증 또는 비만을 효과적으로 예방 또는 치료 혹은 개선할 수 있다.
Vitamin tree leaf powder or extract thereof of the present invention can reduce the weight of the subject and reduce the metabolic abnormalities in the subject, such as hyperlipidemia or the like by reducing the content of cholesterol and triglycerides, such as blood, liver and heart tissue, etc. It can effectively prevent, treat or improve obesity.
도 1은 본 발명의 비타민나무잎분말이 고지방을 급여한 마우스의 식이섭취량에 미치는 영향을 나타낸 그림이다. 평균±표준오차, ab실험군간의 다른 문자는 유의적 차이가 있음(p < 0.05).
도 2는 본 발명의 비타민나무잎 차분말이 고지방을 급여한 마우스의 체중변화에 미치는 영향을 나타낸 그림이다. 평균±표준오차, ab실험군간의 다른 문자는 유의적 차이가 있음(p < 0.05).
도 3은 본 발명의 비타민나무잎 차분말이 고지방을 급여한 마우스의 식이섭취량에 미치는 영향을 나타낸 그림이다. 평균±표준오차, ab실험군간의 다른 문자는 유의적 차이가 있음(p < 0.05).
도 4는 본 발명의 비타민나무잎 차분말이 고지방을 급여한 마우스의 내장지방 무게에 미치는 영향을 나타낸 그림이다. 평균±표준오차, ab실험군간의 다른 문자는 유의적 차이가 있음(p < 0.05).
도 5는 본 발명의 비타민나무잎 차분말이 고지방을 급여한 마우스의 혈장의 지질 함량에 미치는 영향을 나타낸 그림이다. 평균±표준오차, ab실험군간의 다른 문자는 유의적 차이가 있음(p < 0.05).
도 6은 본 발명의 비타민나무잎 차분말이 고지방을 급여한 마우스의 간조직의 지질 함량에 미치는 영향을 나타낸 그림이다. 평균±표준오차, abc실험군간의 다른 문자는 유의적 차이가 있음(p < 0.05).
도 7은 본 발명의 비타민나무잎 차분말이 고지방을 급여한 마우스의 분변의 지질 함량에 미치는 영향을 나타낸 그림이다. 평균±표준오차, abcd실험군간의 다른 문자는 유의적 차이가 있음(p < 0.05).
도 8은 본 발명의 비타민나무잎 차분말이 고지방을 급여한 마우스의 혈장의 GOT와 GPT 활성에 미치는 영향을 나타낸 그림이다. 평균±표준오차, ab실험군간의 다른 문자는 유의적 차이가 있음(p < 0.05).
도 9는 본 발명의 비타민나무잎 차분말이 고지방을 급여한 마우스의 적혈구의 지질과산화물 함량에 미치는 영향을 나타낸 그림이다. 평균±표준오차, ab실험군간의 다른 문자는 유의적 차이가 있음(p < 0.05).1 is a diagram showing the effect of the vitamin leaf powder of the present invention on the dietary intake of mice fed high fat. Mean ± standard error, ab There was a significant difference in the other characters between the experimental groups (p <0.05).
Figure 2 is a diagram showing the effect of the vitamin tree leaf tea powder of the present invention on the weight change of mice fed high fat. Mean ± standard error, ab There was a significant difference in the other characters between the experimental groups (p <0.05).
Figure 3 is a diagram showing the effect of the vitamin leaf tea powder of the present invention on the dietary intake of mice fed high fat. Mean ± standard error, ab There was a significant difference in the other characters between the experimental groups (p <0.05).
Figure 4 is a diagram showing the effect of vitamin tree leaf tea powder of the present invention on the weight of visceral fat of mice fed high fat. Mean ± standard error, ab There was a significant difference in the other characters between the experimental groups (p <0.05).
5 is a diagram showing the effect of the vitamin leaf tea powder of the present invention on the plasma lipid content of mice fed high fat. Mean ± standard error, ab There was a significant difference in the other characters between the experimental groups (p <0.05).
Figure 6 is a diagram showing the effect of the vitamin leaf tea powder of the present invention on the lipid content of liver tissue of mice fed high fat. Mean ± standard error, there was a significant difference in the other letters between the abc experimental group (p <0.05).
Figure 7 is a diagram showing the effect of the vitamin leaf tea powder of the present invention on the lipid content of feces of mice fed high fat. Mean ± standard error, there was a significant difference in the other characters between the abcd experimental group (p <0.05).
Figure 8 is a diagram showing the effect of the vitamin leaf tea powder of the present invention on the GOT and GPT activity of the plasma of mice fed high fat. Mean ± standard error, ab There was a significant difference in the other characters between the experimental groups (p <0.05).
9 is a diagram showing the effect of the vitamin leaf tea powder of the present invention on the lipid peroxide content of red blood cells of mice fed high fat. Mean ± standard error, ab There was a significant difference in the other characters between the experimental groups (p <0.05).
본 발명은 이하 실시예를 통하여 좀더 구체적으로 설명될 것이다. 이러한 실시예는 단지 본 발명이 좀 더 이해될 수 있도록 예시적으로 제시되는 것이므로, 이들 실시예로서 본 발명의 범위를 한정해서는 안 될 것이다.
The invention will be explained in more detail through the following examples. These examples are presented by way of example only, so that the present invention may be more understood, these examples should not limit the scope of the invention.
실시예 1: 시료의 준비 및 실험 방법Example 1 Sample Preparation and Experimental Method
1-1. 비타민나무잎분말 시료의 준비1-1. Preparation of Vitamin Tree Leaf Powder Sample
순천시 승주읍의 순천시농업기술센터에서 자생하는 비타민나무의 어린 잎(3∼5 cm)을 3월에 채취를 한 후 깨끗하게 세척하고 건조한 다음, 이를 믹서기에 넣고 입자 크기가 40∼60 메쉬(mesh)가 되도록 분쇄하여 비타민나무잎분말을 제조하였다.
The young leaves (3 ~ 5 cm) of vitamin trees growing in Suncheon-si Agricultural Technology Center in Seungju-eup, Suncheon-si are collected in March, washed, dried and put into a blender and have a particle size of 40-60 mesh. Grinding to make a vitamin tree leaf powder.
1-2. 비타민나무잎 차분말 시료의 준비1-2. Preparation of Vitamin Tree Leaf Tea Powder Sample
상기 실시예 1-1에서 채취한 비타민나무의 어린 잎을 덖음차로 빚은 다음, 이를 믹서기에 넣고 입자 크기가 40∼60 메쉬(mesh)가 되도록 분쇄하여 비타민나무잎 차분말로 사용하였다. 덖음차는 비타민나무잎을 350℃의 가마솥에서 3분간 살청하여 꺼낸 다음 5분간 비비고 그 다음 200℃ 가마솥에서 5분간 덖고 꺼내어 비빈 후 150℃에서 다시 덖고 비빈 다음 100℃ 이하에서 천천히 10분간 덖은 다음 건조기에서 수분을 제거하는 과정을 통하여 제조하였다.
After forming the young leaves of the vitamin tree collected in Example 1-1 with a teapot, it was put into a blender and pulverized to a particle size of 40 ~ 60 mesh (mesh) was used as a tea leaf tea powder. 덖 For tea, remove the vitamin leaves from the cauldron at 350 ° C for 3 minutes, rub it for 5 minutes, then squeeze it for 5 minutes at 200 ° C cauldron. It was prepared through the process of removing moisture from.
1-3. 실험동물 사육1-3. Breeding experimental animals
실험동물은 4주령의 수컷 ICR 마우스 24마리를 바이오제노믹스(Biogenomics, Seoul, Korea)로부터 구입하였다. 마우스는 1주간 고형식이로 적응시킨 후 난괴법에 의하여 정상군, 고지방대조군, 고지방-비타민나무잎분말군, 고지방-1% 비타민나무잎 차분말군(HF-1%VT)과 고지방-5% 비타민나무잎 차분말군(HF-5%VT)으로 나누어 6주간 사육하였다. 동물 사육실의 환경은 항온(22±2℃), 항습(50±4%), 12시간 간격(08:00~20:00)의 광주기로 일정한 조건을 유지하고 동물들은 폴리카보네이트 사육상자(polycarbonate cage)에 두 마리씩 분리하여 사육하였다.Experimental animals were purchased from Biogenomics, Seoul, Korea, 24 male ICR mice of 4 weeks old. Mice were acclimated to solid diet for 1 week and then normal mass, high fat control group, high fat-vitamin tree leaf powder group, high fat-1% vitamin tree leaf tea powder group (HF-1% VT) and high fat-5 by egg mass method. The fruit was divided into% vitamin leaf tea powder group (HF-5% VT) for 6 weeks. The environment of the animal cage is maintained at constant temperature (22 ± 2 ℃), humidity (50 ± 4%), and 12 hour intervals (08: 00 ~ 20: 00). Two birds were separated and bred.
본 실험에 사용한 기본식이는 AIN-76의 식이조성에 준하였으며 단백질 급원으로는 카제인(Murray, UK)을 공급하고, 탄수화물 급원은 옥수수 전분(신동방), 지방 급원으로는 옥수수 기름(제일제당)을 사용하였다. 고지방 식이군들은 총 열량의 37%(3% corn oil + 18% lard)를 지방으로 공급하였다. 라드(Lard)는 롯데삼강으로부터 구입하였다. 비타민나무잎분말은 식이에 1%가 되도록 조제(표 1 참조)하여 급여하였으며 식이와 식수는 자유롭게 섭취(ad libitum)하도록 하였고, 모든 실험식이는 사육기간 동안 냉장 보관하였다. 사육기간 마지막 5일 동안 분변을 수집하여 건조시킨 후 지질측정에 사용하였다.
The basic diet used in this experiment was based on the dietary composition of AIN-76. The protein source is casein (Murray, UK), the carbohydrate source is corn starch (Xindongbang), and the fat source is corn oil (Cheil Sugar). Used. High-fat diets fed 37% of the total calories (3% corn oil + 18% lard) as fat. Lard was purchased from Lotte Samkang. Vitamin leaf powder was prepared to pay (see Table 1), so that 1% of the dietary intake of dietary and drinking water is free (ad libitum ) and all experimental diets were refrigerated during the breeding period. Feces were collected and dried during the last 5 days of the breeding period and used for lipid measurement.
1-4. 실험동물의 혈장 및 장기 채취1-4. Plasma and Organ Collection of Laboratory Animals
사육이 끝난 실험동물은 희생 전 12시간 동안 절식시킨 후 에테르를 흡입시켜 마취시킨 다음 복부 하대정맥(inferior vena cava)으로부터 공복혈액을 채취하였다. 헤파린 처리된 혈액은 3,000 rpm(4℃)에서 15분간 원심분리하여 혈장을 분리하였다. 실험동물의 장기조직은 혈액 채취 후 즉시 적출하여 PBS(phosphate buffered saline) 용액으로 수차례 헹군 후 표면의 수분을 제거하였으며, 즉시 액체질소로 급냉시켜 -70℃에 보관하였다.
Animals were bred for 12 hours before sacrifice, anesthetized with ether, and fasted blood was collected from the inferior vena cava. Heparinized blood was centrifuged at 3,000 rpm (4 ° C.) for 15 minutes to separate plasma. The organ tissues of the experimental animals were immediately extracted after blood collection, rinsed several times with PBS (phosphate buffered saline) solution, and then water was removed from the surface, and immediately quenched with liquid nitrogen and stored at -70 ° C.
1-5. 실험동물의 혈장, 간조직 및 변 중의 지질 함량 측정1-5. Measurement of Lipid Content in Plasma, Liver and Stool in Laboratory Animals
혈장 중의 중성지질 함량은 Mㆌller의 방법(Mㆌller PH. 1977. A fully enzymatic triglyceride determination. J Clin Chem Clin Biochem 15: 457-464.)으로 조제된 키트(아산제약, 한국)를 사용하여 측정하였다. 총 콜레스테롤 함량과 HDL-콜레스테롤 함량은 Richmond의 방법(Richmond V. 1976. Use of cholesterol oxidase for assay of total and free cholesterol in serum continuous flow analysis. Clin Chem 22: 1579-1588.)으로 조제된 키트(아산제약, 한국)를 사용하였다. 한편, 간조직과 변의 지질 함량은 Folch 등의 방법(Folch J, Mee L, Stanley GSH. 1975. A simple method for the isolation and purification of total lipid from animal tissues. J Biol Chem 226: 497-509.)에 준하여 클로로포름:메탄올(2:1,v/v) 혼합액으로 지질을 추출한 후 혈액과 동일한 방법으로 측정하여 농도를 구하였다.
Neutral lipid content in plasma was determined using a kit prepared by M'ller's method (M ㆌ ller PH. 1977. A fully enzymatic triglyceride determination. J Clin Chem Clin Biochem 15: 457-464.) Measured. Total cholesterol content and HDL-cholesterol content were determined by Richmond's method (Richmond V. 1976. Use of cholesterol oxidase for assay of total and free cholesterol in serum continuous flow analysis. Clin Chem 22: 1579-1588.) Pharmaceutical, Korea). Lipid content of liver tissues and feces was determined by Folch et al. (Folch J, Mee L, Stanley GSH. 1975. A simple method for the isolation and purification of total lipid from animal tissues. J Biol Chem 226: 497-509.) Lipids were extracted with chloroform: methanol (2: 1, v / v) mixture and measured in the same way as blood to determine the concentration.
1-6. 혈장의 GOT와 GPT 활성 측정1-6. Measurement of GOT and GPT Activity in Plasma
간독성의 생화학적 지표로 널리 알려져 있는 혈장의 glutamic-oxaloacetic transaminase(GOT)와 glutamic-pyruvic transaminase(GPT) 활성도는 생화학분석기(FUJI FILM DRI-CHEM, 3500I)를 이용하여 측정하였다.
Glutamic-oxaloacetic transaminase (GOT) and plasma glutamic acid are widely known as biochemical markers of hepatotoxicity. Glutamic-pyruvic transaminase (GPT) activity was measured using a biochemical analyzer (FUJI FILM DRI-CHEM, 3500I).
1-7. 실험동물의 적혈구 분리 및 지질과산화물 측정1-7. Isolation of Red Blood Cells and Lipid Peroxide in Laboratory Animals
실험동물의 혈액으로부터 혈장과 연막(buffy coat)을 완전히 제거한 후 McCord와 Fridovich의 방법(McCord JM, Fridovich I. 1969. Superoxide dismutase: An enzymatic function for erythrocuprein (Hemocuprein). J Biol Chem 244: 6049-6055.)에 준하여 적혈구를 분리하였다. 즉 분리한 적혈구는 0.9% 생리식염수로 3회 세척한 후 증류수로 용해한 다음 효소원으로 사용하였다. 적혈구의 헤모글로빈 함량은 키트(아산제약, 한국)로 측정하였다.McCord and Fridovich's method (McCord JM, Fridovich I. 1969. Superoxide dismutase: An enzymatic function for erythrocuprein (Hemocuprein). J Biol Chem 244: 6049-6055). Red blood cells were separated according to. That is, the isolated red blood cells were washed three times with 0.9% saline solution, dissolved in distilled water, and used as an enzyme source. The hemoglobin content of erythrocytes was measured with a kit (Asan Pharmaceutical, Korea).
적혈구 중의 지질과산화물 함량은 Tarladgis 등의 방법(Tarladgis BG, Pearson AM, Dugan LR. 1964. Chemistry of the 2-thiobarbituric acid test for determination of oxidative rancidity in foods. J Sci Food Agri 15: 602-607.)에 준하여 측정하였다. 지질과산화물의 지표물질인 MDA(malondialdehyde) 함량은 테트라메톡시프로판(tetramethoxypropane) 표준검량선에 준하여 나타내었다.Lipid peroxide content in erythrocytes was determined by Tarladgis et al. (Tarladgis BG, Pearson AM, Dugan LR. 1964. Chemistry of the 2-thiobarbituric acid test for determination of oxidative rancidity in foods.J Sci Food Agri 15: 602-607.) It measured accordingly. The content of MDA (malondialdehyde), an indicator of lipid peroxides, is expressed according to the tetramethoxypropane standard calibration curve.
1-8. 통계처리1-8. Statistical processing
실험결과는 SPSS package 프로그램을 이용하여 실험군당 평균±표준오차로 표시하였고 각 군간의 평균치의 통계적 유의성 검정은 one-way ANOVA를 실시하고 다군간의 차이는 p<0.05 수준에서 던칸의 다검정 테스트(Duncan's multiple test)로 사후 검정하였다.
The experimental results were expressed as the mean ± standard error per experimental group using the SPSS package program.The statistical significance test of the mean value between each group was performed by one-way ANOVA and the difference between the multi-group was Duncan's multi-test (p <0.05). Duncan's multiple test) was used for post test.
실시예 2: 비타민나무잎의 섭취에 따른 실험동물의 체중, 식이섭취량 및 내장지방 무게의 변화 측정Example 2 Measurement of Changes in Body Weight, Dietary Intake and Visceral Fat Weight of Experimental Animals According to Intake of Vitamin Tree Leaves
상기 실시예 1에 기재된 방법에 따라 실시예 1-1의 비타민나무잎분말이 고지방식이를 급여한 마우스의 체중에 미치는 영향을 하기 표 2에 나타내었으며, 일일 식이섭취량과 내장지방 무게를 각각 도 1과 표 3에 나타내었다. 또한, 상기 실시예 1-2의 비타민나무잎 차분말이 고지방식이를 급여한 마우스의 체중에 미치는 영향을 도 2에 나타내었으며, 일일 식이섭취량과 내장지방 무게를 각각 도 3 및 도 4에 나타내었다.The effect of the vitamin tree leaf powder of Example 1-1 on the body weight of the mice fed the high fat diet according to the method described in Example 1 is shown in Table 2 below, and shows the daily dietary intake and visceral fat weight, respectively. 1 and Table 3. In addition, the effect of the vitamin tree leaf tea powder of Example 1-2 on the weight of the mice fed the high fat diet is shown in Figure 2, the daily dietary intake and visceral fat weight is shown in Figures 3 and 4, respectively. .
비타민나무잎분말이 고지방식이를 급여한 마우스의 체중에 미치는 영향을 살펴보면, 실험 개시 때의 마우스 체중은 실험군간 유사하였으나, 실험 3주때부터 열량의 37%를 지방으로 급여한 고지방대조군이 정상군에 비하여 유의적인 체중증가를 보였다. 그러나 비티민나무잎분말 급여군의 경우 6주동안 고지방대조군에 비하여 유의적인 체중감소를 보였다(표 1 참조). 이러한 결과는 도 1에서 보는 바와 같이 비타민나무잎분말 급여시 1주에서 2주까지 식이섭취량이 고지방대조군에 비하여 유의적으로 낮았으며, 3주경에 식이섭취량이 회복된 것은 마우스가 비타민나무잎분말 식이에 적응한 것으로 사료된다. 따라서 실험 종료시 비타민나무잎분말군의 식이섭취량이 고지방대조군과 유사하였으나 체중증가는 효과적으로 억제되었다. The effects of vitamin tree leaf powder on the body weight of mice fed high fat diet were similar to those of the experimental group at the beginning of the experiment, but the high-fat control group fed 37% of calories as fat from the 3 weeks of the experiment was normal. There was a significant weight gain compared to However, the WT-treated group showed significant weight loss for 6 weeks compared to the high-fat control group (see Table 1). As shown in FIG. 1, when the vitamin tree leaf powder was fed, the dietary intake from 1 week to 2 weeks was significantly lower than that of the high-fat control group. It seems to have been adapted to. Therefore, at the end of the experiment, the dietary intake of the vitamin leaf group was similar to that of the high fat control group, but the weight gain was effectively suppressed.
또한, 내장지방량 측정을 위하여 부고환지방, 신장주변 및 장간막의 흰색지방 무게를 측정한 결과 신장주변 지방무게는 실험군간에 차이가 없었으나 부고환 지방무게는 고지방대조군이 정상군에 비하여 1.6배 높았다. 그러나 비타민나무잎분말 급여는 고지방으로 인해 증가된 부고환 지방무게를 유의적으로 낮추었으며 총 내장지방 무게는 약 30% 유의적인 감소를 보였다(표 3 참조).
In addition, as a result of measuring white fat weight of epididymal fat, kidney and mesentery for the measurement of visceral fat, there was no difference between the experimental groups in the perirenal fat weight, but the epididymal fat weight was 1.6 times higher in the high fat control group than the normal group. However, vitamin leaf supplementation significantly lowered the epididymal fat weight due to high fat and total visceral fat weight decreased by about 30% (see Table 3).
한편, 비타민나무잎 차분말이 고지방식이를 급여한 마우스의 체중에 미치는 영향을 살펴보면, 실험 종료 6주에는 고지방대조군의 체중이 정상군에 비하여 약 18% 증가하였으나 비타민나무잎 차분말 급여군은 유의적이지 않으나 체중이 고지방대조군에 비하여 감소하는 경향이었다(도 2 참조). 그리고 고지방군들이 정상식이군보다 일일 식이섭취량은 낮았으며, 비타민나무잎 차분말은 식이섭취량에는 영향을 미치지 않았다(도 3 참조). 체중단위당 부고환지방 무게는 비타민나무잎 차분말을 1%와 5% 급여시 고지방대조군에 비하여 각각 22%와 28%의 유의적인 감소를 보였고, 장간막 지방무게 역시 감소경향을 보임으로써 총 내장지방 무게가 유의적으로 감소되었다(도 4 참조).
On the other hand, the effects of vitamin leaf tea powder on the body weight of the mice fed the high fat diet showed that the weight of the high fat control group increased about 18% compared to the normal group at the end of the 6 weeks. Although not an enemy, the weight tended to decrease compared to the high fat control group (see FIG. 2). And high-fat group was lower than the daily dietary intake than the normal diet group, vitamin leaf tea powder did not affect the dietary intake (see Figure 3). The epididymal fat weight per unit of body weight decreased by 22% and 28%, respectively, compared to the high-fat control group when 1% and 5% vitamin tree leaf tea powder was fed, and the mesenteric fat weight also decreased. Significantly decreased (see FIG. 4).
실시예 3: 비타민나무잎의 섭취에 따른 실험동물의 혈장, 간조직 및 분변 중의 지질 함량에 미치는 영향Example 3: Effect of Vitamin Tree Leaves on Lipid Contents in Plasma, Liver and Feces of Experimental Animals
비타민나무잎분말의 섭취에 따른 실험동물의 혈장, 간조직 및 분변 중의 지질함량을 표 4에 나타내었으며, 비타민나무잎 차분말의 섭취에 따른 실험동물의 혈장, 간조직 및 분변 중의 지질함량을 각각 도 5 내지 7에 나타내었다.
The lipid content of plasma, liver tissue and fecal lipids intake of vitamin tree leaf powder is shown in Table 4, and the lipid content of plasma, liver tissue and fecal tissue of intake vitamin vitamin leaf tea powder, respectively. 5 to 7 are shown.
상기 표 4에서 볼 수 있는 바와 같이, 고지방식이는 혈장과 간조직의 지질 함량을 유의적으로 증가시키는데(Ghasi S, Nwobodo E, Ofili JO. 2000. Hypocholesterolemic effects of crude extract of leaf of Moringa oleifera Lam in high-fat diet fed wistar rats. Journal of Ethnopharmacology 69: 21-25.), 본 실험에서도 6주간의 고열량 섭취는 정상군에 비해 혈장 중의 중성지질과 총 콜레스테롤을 유의적으로 증가시켰다. 그러나 혈장의 중성지질과 총 콜레스테롤 함량은 비타민나무잎분말 급여시 고지방대조군에 비해 유의적인 감소를 보임으로써 비타민나무잎분말은 고지방을 급여한 마우스 혈장의 지질을 개선하는데 우수하였다. As can be seen in Table 4, high fat diet significantly increases the lipid content of plasma and liver tissue (Ghasi S, Nwobodo E, Ofili JO. 2000. Hypocholesterolemic effects of crude extract of leaf of Moringa oleifera Lam In high-fat diet fed wistar rats.Journal of Ethnopharmacology 69: 21-25.), the six-week high calorie intake significantly increased triglyceride and total cholesterol in plasma compared to normal group. However, the triglyceride and total cholesterol content of plasma showed a significant decrease compared to the high fat control group when vitamin leaf supplements were fed.
6주간의 고지방식이 급여는 간조직의 중성지질과 콜레스테롤 함량을 정상군에 비하여 유의적으로 높였다. 그러나 비타민나무잎분말 급여는 간조직의 중성지질 함량과 콜레스테롤 함량을 고지방대조군에 비하여 유의적으로 낮추었다. Six-week high-fat diet significantly increased hepatic triglyceride and cholesterol levels compared to the normal group. However, vitamin leaf supplementation significantly lowered triglyceride content and cholesterol content of liver tissue compared to high fat control group.
그리고 비타민나무잎분말이 고지방을 섭취한 마우스의 지질 흡수 또는 배설에 미치는 영향을 살펴보기 위하여 변 중의 지질 함량을 측정하였다. 그 결과 콜레스테롤 함량은 고지방대조군이 정상군에 비하여 낮은 반면, 중성지질은 약 2.6배 높았다. 그러나 비타민나무잎분말 급여는 고지방대조군에 비하여 변으로의 중성지질 배설과 콜레스테롤 함량을 각각 1.7배와 1.4배 유의적으로 증가시켰다. 이는 비타민나무잎분말이 지방의 흡수를 저해하거나 배설을 촉진시킴으로써 혈중 지질 개선과 조직 중의 지질 축적을 억제하는데 기여하는 것으로 사료되었다.
In addition, the lipid content in feces was measured to examine the effect of vitamin leaf powder on lipid absorption or excretion in mice fed high fat. As a result, the cholesterol content of the high fat control group was lower than that of the normal group, while the neutral lipid was about 2.6 times higher. However, vitamin leaf supplementation significantly increased stool neutral lipid excretion and cholesterol contents 1.7 times and 1.4 times, respectively, compared to the high fat control group. This suggests that the vitamin leaf powder contributes to the improvement of blood lipids and the accumulation of lipids in tissues by inhibiting fat absorption or promoting excretion.
한편, 도 5 내지 도 7에서 볼 수 있는 바와 같이, 비타민나무잎 차분말 급여시 고지방대조군에 비하여 혈장의 중성지질은 19% ~ 24% 유의적으로 낮추었으며, 총 콜레스테롤 함량은 18% ~ 29% 유의적으로 낮추었다. 5% 비타민나무잎 차분말 급여가 1% 비타민나무잎 차분말 급여시보다 유의적이지는 않았으나 효과적이었다. HDL-콜레스테롤 함량은 군간의 차이가 없었다. 간조직 중의 콜레스테롤 함량은 비타민나무잎 차분말 급여시 고지방대조군에 비하여 유의적으로 낮았으며, 중성지질 함량은 고지방대조군에 비하여 5% 급여수준에서만 37% 유의적인 감소 효과를 나타내었다. 변으로 중성지질 배설은 비타민나무잎 차분말 급여시 고지방대조군에 비하여 급여수준이 높을수록 유의적으로 증가하였다.
On the other hand, as can be seen in Figures 5 to 7, when the vitamin leaf tea powder supplementation significantly lowered the plasma neutral lipid 19% ~ 24% compared to the high fat control group, total cholesterol content 18% ~ 29% Significantly lowered. The 5% vitamin leaf tea powder supplementation was less effective than the 1% vitamin tree leaf tea powder supplementation. HDL-cholesterol content did not differ between groups. Cholesterol content in liver tissue was significantly lower than that of high fat control group when fed the vitamin leaf tea powder, and triglyceride content was 37% significantly lower than that of high fat control group. Fecal triglyceride excretion was significantly increased as the level of salary was higher than that of high fat control group.
실시예 4: 비타민나무잎의 섭취에 따른 실험동물의 간독성 지표에 미치는 영향Example 4 Effect on the Hepatotoxicity Indicators of Experimental Animals According to the Intake of Vitamin Tree Leaves
비타민나무잎분말의 섭취에 따른 실험동물의 간독성 지표인 혈장의 GOT와 GPT 활성을 표 5에 나타내었으며, 비타민나무잎 차분말의 섭취에 따른 실험동물의 간독성 지표인 혈장의 GOT와 GPT 활성을 도 8에 나타내었다.
Table 5 shows the GOT and GPT activity of plasma, which is an indicator of hepatotoxicity of experimental animals, according to the intake of vitamin tree leaf powder. 8 is shown.
고지방식이는 간독성 지표인 혈장의 GOT와 GPT 활성을 유의적으로 높이는 것으로 나타났으나, 상기 표 5 및 도 8에서 볼 수 있는 바와 같이, 비타민나무잎분말 급여시 이들 GOT 및 GPT 활성이 고지방대조군에 비하여 유의적으로 개선되었으며, 비타민나무잎 차분말 급여시 GPT 활성이 유의적으로 고지방대조군에 비하여 유의적으로 개선된 것을 확인할 수 있었다. 다만, 비타민나무잎 차분말 급여시 GOT 활성은 실험군간의 차이가 나타나지 않았다.
High-fat diet was shown to significantly increase the GOT and GPT activity of plasma, which is an indicator of hepatotoxicity, as shown in Table 5 and Figure 8, when the vitamin tree leaf powder supplemented GOT and GPT activity is high fat control group Compared to the high fat control group, GPT activity was significantly improved compared to the high fat control group. However, GOT activity did not show any difference among the experimental groups.
실시예 5: 비타민나무잎의 섭취에 따른 실험동물의 적혈구 중의 지질과한화물 생성에 미치는 영향Example 5 Effect of Lipid Excess in Red Blood Cells of Experimental Animals on Intake of Vitamin Tree Leaves
비타민나무잎분말의 섭취에 따른 실험동물의 적혈구 중의 지질과산화물 함량을 표 6에 나타내었으며, 비타민나무잎 차분말의 섭취에 따른 실험동물의 적혈구 중의 지질과산화물 함량을 도 9에 나타내었다.
The lipid peroxide content in the red blood cells of the experimental animals according to the intake of vitamin tree leaf powder is shown in Table 6, and the lipid peroxide content in the red blood cells of the experimental animals according to the intake of the vitamin tree leaf tea powder.
상기 표 6 및 도 9에서 볼 수 있는 바와 같이, 고지방식이는 적혈구의 지질과산화물 함량을 유의적으로 증가시켰으나 비타민나무잎분말 급여시 고지방대조군에 비하여 유의적으로 개선되었으며, 비타민나무잎 차분말 급여시 적혈구 과산화물 생성이 각각 약 15%와 17% 유의적으로 억제되었다. As can be seen in Table 6 and Figure 9, the high-fat diet significantly increased the lipid peroxide content of red blood cells, but significantly improved compared to the high-fat control group when vitamin leaf supplements were fed, vitamin tree leaf tea supplements. Red blood cell peroxide production was significantly inhibited by about 15% and 17%, respectively.
Claims (7)
5. The composition of claim 1, wherein the composition is a food or food material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100020969A KR101166852B1 (en) | 2010-03-09 | 2010-03-09 | Compositions comprising Hippophae rhamnoides L. leaves or extracts thereof for amelioration of body lipid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100020969A KR101166852B1 (en) | 2010-03-09 | 2010-03-09 | Compositions comprising Hippophae rhamnoides L. leaves or extracts thereof for amelioration of body lipid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20110101743A true KR20110101743A (en) | 2011-09-16 |
| KR101166852B1 KR101166852B1 (en) | 2012-07-19 |
Family
ID=44953718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020100020969A KR101166852B1 (en) | 2010-03-09 | 2010-03-09 | Compositions comprising Hippophae rhamnoides L. leaves or extracts thereof for amelioration of body lipid |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101166852B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150025545A (en) * | 2013-08-29 | 2015-03-11 | 신 훈 강 | Composition for lowering levels of lipid or glucose containing the juice of Hippophae rhamnoides L. |
| KR20210032619A (en) * | 2019-09-17 | 2021-03-25 | 박경선 | Preparation method of olive soup using olive leaf |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101327232A (en) * | 2008-07-22 | 2008-12-24 | 山东省医药工业研究所 | Method for preparing Hippophae rhamnoides flavones separated and purified by polyamide and uses thereof |
-
2010
- 2010-03-09 KR KR1020100020969A patent/KR101166852B1/en active IP Right Grant
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150025545A (en) * | 2013-08-29 | 2015-03-11 | 신 훈 강 | Composition for lowering levels of lipid or glucose containing the juice of Hippophae rhamnoides L. |
| KR20210032619A (en) * | 2019-09-17 | 2021-03-25 | 박경선 | Preparation method of olive soup using olive leaf |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101166852B1 (en) | 2012-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101361603B1 (en) | Composition for amelioration of body lipid | |
| US20100210722A1 (en) | Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same | |
| KR101464337B1 (en) | Composition for anti-obesity comprising extract of Diospyros lotus as effective component | |
| JP2008174539A (en) | Healthy and functional food for obesity patient using purple-colored potato | |
| US8722614B2 (en) | Adiponectin production enhancer | |
| KR20130102295A (en) | Composition comprising extract of humulus japonicus or humulus scandens for preventing or treating of metabolic diseases | |
| KR101919839B1 (en) | Composition for hepatoprotective and ameliorating hangover containing cricket material enzyme-decomposed with Alcalase | |
| KR101610466B1 (en) | A composition containing complex extracts comprising Vitis sp. and Schisandra chinensis for preventing or treating metabolic syndrome-related diseases | |
| JP2007519715A (en) | A composition comprising a kabonashi extract, a dangwei extract, or a mixed herbal extract thereof as an active ingredient | |
| KR20190003304A (en) | Composition for preventing, improving or treating fatty liver disease comprising Gryllus bimaculatus extract as effective component | |
| KR101166852B1 (en) | Compositions comprising Hippophae rhamnoides L. leaves or extracts thereof for amelioration of body lipid | |
| KR101820096B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating metabolic disease | |
| WO2018066956A1 (en) | Composition comprising schisandrae fructus-containing composite extract for preventing or treating blood circulation-related disease | |
| KR20140137288A (en) | Composition comprising an extract of Alpinia officinarum Hance for preventing and treating hangover or liver disease | |
| KR101516764B1 (en) | A composition containing Humulus japonicus extracts for preventing or treating liver disease or atherosclerosis | |
| KR101692604B1 (en) | Composition comprising pomegranate juice extrated low speeed for improving liver function | |
| JP2008019198A (en) | Insulin resistance-improving composition obtained from plant belonging to genus silybum | |
| JP2002173435A (en) | Antiobestic drug and medication method for the same | |
| KR20220118504A (en) | composition for suppressing obesity | |
| KR20110121239A (en) | Composition comprising skin of onion for preventing or treating lipid metabolism disorder | |
| KR101018404B1 (en) | Compositions for reducing cholesterol comprising extracts of Vaccinium oldhami Miquel leaf as an active ingredient | |
| KR20190135452A (en) | Compositions for Preventing, Improving or Treating Non-Alcoholic Fatty Liver Disease Comprising Combined Extracts of Peach Blossom and Lotus Leaf | |
| JP2012188426A (en) | Lipid metabolism-improving composition | |
| KR100539457B1 (en) | Composition For Preventing And Treating Hyperlipidemia, Arteriosclerosis And Fatty Liver Comprising The Extract Of Sophorae Fructus | |
| JP2021109858A (en) | Agent for preventing or improving metabolic syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20150626 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20160628 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20170628 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20180618 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20190701 Year of fee payment: 8 |